5906-30-9

Usage

Explanation

1-Piperazinesulfonamide(7CI,8CI,9CI) has a molecular formula of C4H10N2O2S, which indicates the number of carbon, hydrogen, nitrogen, oxygen, and sulfur atoms in the compound.

Explanation

It belongs to the piperazine class of compounds, which is a group of chemical structures that includes a six-membered heterocyclic ring with four carbon atoms and two nitrogen atoms.

Explanation

1-Piperazinesulfonamide(7CI,8CI,9CI) contains a sulfonamide functional group, which is a chemical group consisting of a sulfur atom double-bonded to an oxygen atom and single-bonded to a nitrogen atom (-SO2NH2).

Explanation

This chemical compound is a white solid, which describes its color and physical state.

Explanation

1-Piperazinesulfonamide(7CI,8CI,9CI) is soluble in water, meaning it can dissolve in aqueous solutions to form a homogeneous mixture.

Explanation

The compound has various applications in fields such as medicinal chemistry (as a building block for synthesizing pharmaceuticals and biologically active molecules), corrosion inhibition, pesticide production, and the manufacture of dyes and pigments.

Explanation

1-Piperazinesulfonamide(7CI,8CI,9CI) has been studied for its potential as an anticancer and antimicrobial agent, indicating possible future applications in the treatment of cancer and infections.

Piperazine class

Compound class

Sulfonamide functional group

Functional group present

Physical appearance

White solid

Solubility

Soluble in water

Applications

Medicinal chemistry, corrosion inhibition, pesticides, dyes and pigments

Potential therapeutic uses

Anticancer and antimicrobial agent

InChI:InChI=1/C21H26F2N4O2/c1-14(2)26(21(29)24-19-9-6-15(22)11-18(19)23)13-20(28)27(16-7-8-16)12-17-5-4-10-25(17)3/h4-6,9-11,14,16H,7-8,12-13H2,1-3H3,(H,24,29)

Upstream product

• 178312-46-4 1-Aminosulphonyl-4-benzylpiperazine 
• 110-85-0 piperazine 
• 108555-00-6 4-nitrophenyl sulfamate 
• 109-01-3 1-methyl-piperazine 
• 1249611-72-0 2-chloropyridine-3-methylsulfonamide 
• 610799-03-6 tert-butyl 4-sulfamoylpiperazine-1-carboxylate 

Relevant academic research and scientific papers

DUAL ACTION CARBONIC ANHYDRASE INHIBITORS

The present invention is directed to novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety substituted with a heterocycle or phosphinate and having sulfonamide, sulfamate or sulfamide groups. The present invention is also related to the use of these novel carbonic anhydrase IX inhibitors in cancer treatment, especially radiotherapy and chemotherapy and the use in treatment of infections.

Kinetic and mechanistic studies on sulfamate esters: Models of enzyme inhibitors

Many compounds containing a sulfamate moiety, such as NH2SO 2O - are now known to be medicinally important. However, very little is known about their mechanisms of reaction even under non-biological conditions. In this work the vario

Insertion of an aspartic acid moiety into cyclic pseudopeptides: Synthesis and biological characterization of potent antagonists for the human tachykinin NK-2 receptor

A new series of monocyclic pseudopeptide tachykinin NK-2 receptor antagonists has been derived from the lead compound MEN11558. A synthesis for these molecules sharing the same intermediate was designed and performed. The replacement of the succinic moiety with an aspartic acid and the functionalization of its amino group with a wide variety of substituents led to very potent and selective NK-2 antagonists. Best results were obtained through the insertion in position 12 of an amino group with R configuration, linked by a short spacer to a saturated nitrogen heterocycle (morpholine, piperidine, or piperazine). The study led to compounds 54 and 57, endowed with high in vivo potency at very low doses and long duration of action in animal models of bronchoconstriction. In particular 54 and 57 completely inhibited NK-2 agonist induced bronchoconstriction in guinea pig after intratracheal administration at subnanomolar doses (ED50 = 0.27 nmol/kg and 0.15 nmol/kg, respectively).

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1

C-Piperazino-pyridine sulfonamides

This invention relates to compounds of the formula: SPC1 Wherein R1 in the 3- or 5-position is preferably a substituted sulfonamido or a carboxamido group whereas R2 in the 2-, 4- or 6-position is preferably an alkyl- or hydroxyalkyl-piperazinyl group. Said compounds may be used as anti-inflammatory and cardiovascular agents.